HPV Vaccine + Imiquimod + Metformin for Cervical Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial aims to see if additional treatments can boost the immune system to fight cancer caused by the Human Papillomavirus (HPV). The trial will test if combining experimental therapies with standard treatment helps
Cancer Vaccine
Self-Collection Screening for Cervical Cancer Prevention
Recruiting1 award2 criteria
Indianapolis, Indiana
This trial aims to prevent cervical cancer in Kenyan women by combining screening for premalignancies and vaccinating children against HPV. Currently, only a small percentage of women are regularly screened, and very few
Popular Filters
Trials for Cancer Patients
Monoclonal Antibodies
NPX267 for Cancer
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial tests NPX267, an antibody drug that helps the immune system fight cancer by targeting a specific marker on cancer cells. It focuses on patients with certain cancers, including a type of lung cancer, to find a safe and effective dose. The study will monitor side effects and check how well the drug works against tumors.
CAR T-cell Therapy
STIL101 Therapy for Pancreatic Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is testing a treatment called STIL101 for injection in patients with pancreatic cancer, colorectal cancer, renal cell cancer, cervical cancer, and melanoma that has spread or cannot be removed by
Trials for Breast Cancer Patients
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Estrogen Receptor Antagonist
Tucatinib + Trastuzumab for HER2-Positive Cancers
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Trials for Metastatic Patients
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Estrogen Receptor Antagonist
Tucatinib + Trastuzumab for HER2-Positive Cancers
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Alkylating agents
Pembrolizumab + Chemoradiotherapy for Cervical Cancer
Recruiting1 awardPhase 3
Los Angeles, California
This trial will compare the effectiveness of two cancer treatments for locally advanced cervical cancer. The first treatment is pembrolizumab plus concurrent chemoradiotherapy and the second is placebo plus concurrent chemoradiotherapy. The study's primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.
Predictive Assays for Cervical Cancer
Recruiting1 award
Toronto, Ontario
This trial will compare different techniques for measuring how much oxygen is reaching a patient's cervix cancer and how much pressure is in the tissues around the tumor. The goal is to see which technique is most accurate in determining a patient's chances of survival following radiation therapy.
Phase 3 Trials
Alkylating agents
Pembrolizumab + Chemoradiotherapy for Cervical Cancer
Recruiting1 awardPhase 3
Los Angeles, California
This trial will compare the effectiveness of two cancer treatments for locally advanced cervical cancer. The first treatment is pembrolizumab plus concurrent chemoradiotherapy and the second is placebo plus concurrent chemoradiotherapy. The study's primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.
Platinum-based Chemotherapy
Chemo-Radiation for Early-Stage Cervical Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying how well giving chemotherapy and pelvic radiation therapy together with or without additional chemotherapy works in treating patients with high-risk early-stage cervical cancer.
Virus Therapy
Volrustomig for Advanced Cervical Cancer
Recruiting1 awardPhase 3
Savannah, Georgia
This trial is testing a new medication called Volrustomig to see if it can help women with advanced cervical cancer. The study focuses on those who haven't seen their cancer progress after initial treatment. Volrustomig might help stop or slow down the growth of cancer cells.
Trials With No Placebo
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Estrogen Receptor Antagonist
Tucatinib + Trastuzumab for HER2-Positive Cancers
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is for people with solid tumors that make too much HER2 or a different type of HER2. Participants will get tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get fulvestrant. The trial will look at side effects.
Behavioral Intervention
Cervical Cancer Screening Program for Asian American Women
Recruiting1 award3 criteria
Philadelphia, Pennsylvania
This trial will evaluate whether providing a self-sampling kit along with an educational program and navigation assistance increases cervical cancer screening rates in underserved Korean and Vietnamese American women.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' ā so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back ā in general, verified trials respond to patients within a few days.